Form 4 Filing for Benitec Biopharma Inc. - Officer/Director Transaction

David Matthew Friedman, a director at Benitec Biopharma Inc., acquired 35,000 stock options on May 26, 2026. These options, with an exercise price of $11.45, are set to vest in full by May 26, 2027, or immediately prior to the next annual stockholder meeting. Mr. Friedman holds these options for the benefit of Averill Master Fund, Ltd. and Averill Madison Master Fund, Ltd., which may have an indirect pecuniary interest due to management agreements with Suvretta Capital Management, LLC. Mr. Friedman disclaims beneficial ownership of these options.